Antithrombogenic Products
Covalent heparin attachment - one step
A) Proprietary commercial application Clotting times
ID of a polysulfone tube was coated with a covalently bound water-based heparin coating. Modified Lee-White clotting time test from NAMSA on Steam-sterilized parts.
Clotting time changes were significant. This information combined with un-coated data suggests that the Surface Solution samples did reduce clotting time.
B) J.Strony PhD CWRU Thrombin times- human plasma - one step
Two samples of coating resins were prepared. In one, heparin was bound covalently to the supporting resin through a linker and in the other the heparin was not bound. Films 3 mils thick were cast on PE sheets and removed. A control of benzalkonium heparin was prepared by casting the coating resin on PE and post-dipping in the ionic heparin solution. Films were soaked in saline for 24 hours and then removed and placed in fresh saline. Thrombin times for soak solutions, based on a pooled human plasma, yielded IU data shown below.
Lost effectiveness was defined as <1 IU/24 Hour release. Benzalkonium control and unbound heparin were all ineffective at 24 hours or less. The bound heparin is sustained and released over atleast 14 days.
C) Biocascade- Covalent attachment and sustained release measured by Anti Xa
Two separate sections (~1-2 cm 2 each) of films (6-65D) were incubated in isotonic Anti-Xa buffer at 37 o C. At various times (e.g. 1 hr, 24 hr, 48 hr, 1 wk, 2 wk,1,3 and 6 months), the incubation buffer was removed from the surface film and assayed for heparin Anti-Xa activity by the USP Anti-Xa method. Fresh buffer solution was then used to replace the removed buffer and the incubation continued until the next assay point, where the procedure was repeated.
The film released heparin, at a relatively slow rate, resulting in about 20% of the theoretical heparin content being eluted as biologically active heparin in the first month.The film did not change physical shape during the incubation in buffer, but appeared to be hydrophilic and retain its original shape and texture.
The remaining heparin is biologically active and accessible at the surface of the film as measured with the USP Anti-Xa method. This would appear to be an interesting, and stable anti-thrombotic film, as it appears that only small amounts of heparin are eluting from the film after one month, and that the remaining heparin is tightly bound and all heparin is biologically active.
Applications Methods:
▪ Dip
▪ Pad/ Brush
▪ Spray
▪ Flow/Curtain
▪ Gravure/Roll/ Knife Over Roll
Instructions for use
MSDS Sheets for Antithrombogenic Patented Products
MSDS Sheets for Crosslinker A Products
Patented systems use crosslinking agents to bind the supporting polymers to each other for better strength and resistance to solvents, sterilizing materials, heat and body fluids. Crosslinkers also bind to functional groups on the surface to improve adhesion. For drug delivery applications it is possible to bind and immobilize pharmaceutical agents to the surface allowing for sustained release, or surface immobilization.
Coatings2go, LLC is not responsible for the use of any of the information contained, or any product mentioned, in this document, and you must make your own determination of its suitability and completeness for your own use. You should conduct your own testing. All expressed and implied warranties, including any implied warranty of merchantability and warranty of fitness for a particular purpose and warranty arising out of the parties™ course of dealing are hereby disclaimed by C2g. The products are being sold "As Is". You are responsible for handling and disposal according to local, regional and federal regulations. C2g shall not be liable for any incidental or consequential damages. Nothing herein shall be construed as a license or sublicense to operate under any C2g or third party owned patent or as a warranty against infringement of any patent. By placing an order for any of these products and/or by accepting their delivery, the purchaser agrees to the above waivers.
